Medications for Liver Carcinoma

10 results

  • avastin - bevacizumab injection, solution

    (Bevacizumab)
    Genentech, Inc.
    Avastin (bevacizumab) is a VEGF inhibitor used with chemotherapy to treat metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, cervical cancer, ovarian/fallopian tube/peritoneal cancer, and hepatocellular carcinoma. Also indicated for recurrent glioblastoma in adults.
    Medication Details
    Drug Interactions

  • cabometyx - cabozantinib tablet

    (Cabozantinib)
    Exelixis, Inc.
    Cabometyx treats advanced renal cell carcinoma (alone or with nivolumab), hepatocellular carcinoma after sorafenib, and locally advanced or metastatic differentiated thyroid cancer or neuroendocrine tumors (pancreatic and extra-pancreatic) in adults and patients 12 and older after prior therapy.
    Medication Details
    Drug Interactions

  • cyramza - ramucirumab solution

    (Ramucirumab)
    Eli Lilly And Company
    Cyramza is a VEGFR2 antagonist for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma, metastatic non-small cell lung cancer, metastatic colorectal cancer, and hepatocellular carcinoma with alpha fetoprotein of 400 ng/mL or higher after sorafenib.
    Medication Details
    Drug Interactions

  • imfinzi - durvalumab injection, solution

    (Durvalumab)
    Astrazeneca Pharmaceuticals Lp
    Imfinzi is a PD-L1 blocking antibody indicated for adults with multiple cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, hepatocellular carcinoma, endometrial cancer, bladder cancer, and gastric or gastroesophageal junction adenocarcinoma.
    Medication Details
    Drug Interactions

  • keytruda - pembrolizumab injection, powder, lyophilized, for solution

    (Pembrolizumab)
    Merck Sharp & Dohme Llc
    Keytruda is a PD-1-blocking immunotherapy indicated for numerous cancers including melanoma, non-small cell lung cancer, head and neck cancer, bladder cancer, colorectal cancer, gastric cancer, cervical cancer, renal cell carcinoma, endometrial carcinoma, triple-negative breast cancer, and other solid tumors.
    Medication Details
    Drug Interactions

  • lenvima - lenvatinib capsule

    (Lenvatinib)
    Eisai Inc.
    Lenvima treats adults with radioactive iodine-refractory differentiated thyroid cancer, advanced renal cell carcinoma (with pembrolizumab or everolimus), unresectable hepatocellular carcinoma, and advanced endometrial carcinoma (with pembrolizumab) after prior systemic therapy.
    Medication Details
    Drug Interactions

  • opdivo - nivolumab injection

    (Nivolumab)
    E.R. Squibb & Sons, L.L.C.
    Opdivo is a PD-1 blocking antibody indicated for multiple cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, and gastric cancers in adults and select pediatric patients.
    Medication Details
    Drug Interactions

  • stivarga - regorafenib tablet, film coated

    (Regorafenib)
    Bayer Healthcare Pharmaceuticals Inc.
    Stivarga treats adults with previously treated metastatic colorectal cancer, locally advanced or metastatic gastrointestinal stromal tumors (GIST) after imatinib and sunitinib, and hepatocellular carcinoma after sorafenib.
    Medication Details
    Drug Interactions

  • tecentriq - atezolizumab injection, solution

    (Atezolizumab)
    Genentech, Inc.
    Tecentriq is a PD-L1 blocking antibody for treating several cancers in adults: non-small cell and small cell lung cancer, hepatocellular carcinoma, BRAF V600-positive melanoma, alveolar soft part sarcoma (including pediatric patients age 2+), and muscle invasive bladder cancer.
    Medication Details
    Drug Interactions

  • yervoy - ipilimumab injection

    (Ipilimumab)
    E.R. Squibb & Sons, L.L.C.
    Yervoy treats multiple advanced cancers in adults and pediatric patients (12+), including melanoma, renal cell carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell carcinoma—primarily in combination with nivolumab.
    Medication Details
    Drug Interactions